Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.42 |
| ▸ | LIPE | Q05469 | 8/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | GRN | P28799 | 1/20 | 0.39 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21656983 | 0.90 | PDE4B (0.50) | LMNALIPEPDE4BMAPTKDM4E | |
| SCHEMBL21656972 | 0.89 | MAPT (0.48) | LMNAP2RX3LIPEOPRM1OPRD1 | |
| SCHEMBL21656893 | 0.88 | OPRM1 (0.49) | LMNALIPEOPRM1OPRD1OPRK1 | |
| SCHEMBL21656866 | 0.88 | LMNA (0.45) | LMNALIPEOPRM1OPRD1OPRK1 | |
| SCHEMBL21657069 | 0.88 | LMNA (0.56) | LMNAP2RX3LIPEPDE4BMAPK1 | |
| SCHEMBL21656859 | 0.88 | OPRM1 (0.49) | LMNAP2RX3OPRM1OPRD1OPRK1 | |
| SCHEMBL21656483 | 0.86 | MAPT (0.44) | LMNAMAPK1ALDH1A1MAPT | |
| SCHEMBL23228796 | 0.86 | LMNA (0.42) | LMNALIPEALDH1A1MAPT | |
| SCHEMBL21656684 | 0.82 | LMNA (0.64) | LMNAP2RX3LIPEMAPK1OPRM1 | |
| SCHEMBL21656881 | 0.81 | LMNA (0.40) | LMNAP2RX3ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11591289-B2 | Aromatic compounds | Xeniopro GmbH (DE) | 2023-02-28 | — | — | US | disclosed |
| US-20210107863-A2 | NOVEL AROMATIC COMPOUNDS | Xeniopro GmbH (DE) | 2021-04-15 | — | — | US | disclosed |
| US-20200031763-A1 | NOVEL AROMATIC COMPOUNDS | Xeniopro GmbH (DE) | 2020-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11591289-B2 | Aromatic compounds | AHR, TYR, MUSK | LMNA 3083/4885P2RX3 2206/4885LIPE 4390/4885 |
| US-20210107863-A2 | NOVEL AROMATIC COMPOUNDS | AHR, TYR, MUSK | LMNA 3327/4885P2RX3 1886/4885LIPE 4438/4885 |
| US-20200031763-A1 | NOVEL AROMATIC COMPOUNDS | AHR, TYR, MUSK | LMNA 3327/4885P2RX3 1886/4885LIPE 4438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.